Table 2

Quality of life outcomes from the ATTAIN trial [33]

Abatacept (mean change from baseline)

Placebo (mean change from baseline)

P value (abatacept versus placebo)


Physical functioning

5.3

1.2

0.0001

Physical role

6.7

0.8

<0.0001

Pain

8.7

2.2

<0.0001

General health

3.9

0.7

0.0002

Vitality

6.9

1.2

<0.0001

Social functioning

7.4

2.2

<0.0001

Emotional role

6.3

2.0

0.0133

Mental health

4.6

1.1

0.0012

Physical component score

6.5

1.0

<0.0001

Mental component score

5.5

1.7

0.0025

Fatigue VAS

-22.1

-5.3

<0.0001


Quality of life components are shown from the ATTAIN study, which compared abatacept plus methotrexate versus placebo plus methotrexate in patients with rheumatoid arthritis who were refractory to tumor necrosis factor-α inhibition. ATTAIN, Abatacept Trial in Treatment of Anti-TNF Inadequate Responders; MOS, medical outcome study; VAS, visual analog score.

Buch et al. Arthritis Research & Therapy 2008 10(Suppl 1):S5   doi:10.1186/ar2416